Specifically, Kadcyla has exhibited effective therapeutic outcomes in HER2-positive breast cancer by selectively delivering the drug to tumor cells, thereby minimizing its impact on surrounding normal cells [50,51]. Here, ERBB2 is linked to breast carcinoma.